San Francisco, CA (August 24, 2013) - Mytrus Inc. announced today that they have been awarded Frost & Sullivan’s prestigious clinical trials product leadership award for their pioneering electronic informed consent application, enroll™.
Frost & Sullivan, a respected global research organization that tracks more than 250,000 companies, compared Mytrus to other market competitors in a rigorous review that touched on several elements of product design, adoption, ease of use and market potential. At the end of the review, Mytrus was named winner of the North American Product Leadership Award in Clinical Trials for 2013.
"Mytrus has developed a product that makes the cumbersome, but critical process of informed consent simple and efficient for patients and offers sponsors and regulators new opportunities to collect and track important informed consent data analytics," said Prakhar Verma, Industry Analyst at Frost & Sullivan. "Like other truly disruptive innovations, enroll™ is simple yet powerful and defines a new market for collecting clinical trial consent electronically on all research studies"
Informed consent forms typically run 8 to 50 pages of often-complex legal and medical information. Participants frequently fail to read or understand the documents before they consent to participating in a trial. Further, there are no requirements for assessing participants’ understanding of the protocol or risks.
"Informed consent is one of the most important, but often neglected, elements of enrolling patients in clinical trials" said Mytrus CEO Anthony Costello. "We are humbled to receive this award for our work in the area of eConsent and we are encouraged to see the number of companies rushing to adopt more patient-centered tools for clinical research"
According to ClinicalTrials.gov, there were more than 60,000 registered clinical trials ongoing in the United States last June and the number is growing. Studies are often long and complex. The time and effort spent recruiting patients can represent a third of the cost of trials, yet once enrolled in a trial, patients often drop out due to poor understanding of the treatment protocol. All of this contributes, in the end, to higher drug development costs.
A study published earlier this year in the Public Library of Science also showed that patients and investigators receiving information electronically via Mytrus on iPads had far greater comprehension and retention of the material than those receiving the same information on paper.
Earlier this year, inVentiv Health took an equity position in Mytrus, Inc., a pioneer in "virtual clinical trials" and electronic informed consent, as part of a suite of services and technologies inVentiv has assembled to dramatically improve trial efficiency. Mytrus has also partnered with the WIRB-Copernicus Group, the world’s largest provider of regulatory and ethical review services for human research, to deliver enroll™ to customers using the WIRB-Copernicus Group for study ethics review and approval.
Mytrus will accept its award at a gala dinner sponsored by Frost & Sullivan in San Jose, CA on September 11th.
Founded in 2009, Mytrus is a privately held e-clinical technology company specializing in patient-centered electronic informed consent and data collection tools. After receiving the first FDA approvals for remote electronic consent and virtual data collection, Mytrus has gone on to develop new technologies for patients including ePRO and EDC tools usable from home and mobile devices, bio-sample consent tracking technology, site training and e-learning applications, and patient home dashboards for tracking clinical study progress and data. Mytrus also holds an exclusive patent for conducting virtual clinical trials in the US. Mytrus investors include BioClinica and inVentiv Health.